Innate Pharma SA

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the Evercore ISI 4th Annual HealthConX Virtual Conference

Innate Pharma to Participate in the Evercore ISI 4th Annual HealthConX Virtual Conference

Innate Pharma S.A. (IPHA) CEO Mondher Mahjoubi on Q3 2021 Results - Earnings Call Transcript

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma Third Quarter 2021 Report

Innate Pharma Third Quarter 2021 Report

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma highlights new NK cell engager data with partner Sanofi at SITC

Innate Pharma Highlights New NK Cell Engager Data With Partner Sanofi at SITC Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, November 16, 2021, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2021. Participating in the call will be Innate's Chief Executive Officer Mondher Mahjoubi, MD and Chief Medical Officer Joyson Karakunnel, MD, MSc, FACP. Details for the Virtual

Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2022 financial calendar: March 24, 2022: Publication of 2021 financial statements May 10, 2022: Publication of revenue for 1Q2022 May 20, 2022: Annual General Shareholders Meeting September 15, 2022: Publication of half year financial statements November 14, 2022: Publication of revenue for 3Q2022 All financial reports are released before marke

Innate Pharma 2022 Financial Calendar

A clinical trial with an experimental lung cancer drug produced some positive results.

Here's Why Innate Pharma Stock Is Rocketing Higher Today

Innate Pharma SA (NASDAQ: IPHA) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology ( ESMO21 ) Congress 2021. The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT).

What Is Happening With Innate Pharma Stock On Friday?

The stock price of Innate Pharma SA (NASDAQ: IPHA) increased by over 30% pre-market. This is why it happened.

IPHA Stock: Why It Significantly Increased Today

Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.

Monalizumab Data From COAST Trial Presented at ESMO Congress 2021

Innate Pharma S.A. (IPHYF) CEO Mondher Mahjoubi on Q2 2021 Results - Earnings Call Transcript

MARSEILLE, France, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2021. The consolidated financial statements are attached to this press release.

Innate Pharma Reports First Half 2021 Financial Results and Business Update

MARSEILLE, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Wednesday, September 15, 2021, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2021.

Innate Pharma Announces Conference Call and Webcast for First Half 2021 Business Update

The stock price of Innate Pharma SA (NASDAQ: IPHA) increased 47.13% yesterday. This is why it happened.

IPHA Stock: 47.13% Increase Explanation

Innate Pharma SA (NASDAQ:IPHA) stock closed almost 14% higher on Thursday after the Company disclosed two upcoming presentations scheduled at ESMO 2021 Virtual Congress. The presentations include a late-breaker abstract on a Phase 2 trial highlighting the progression-free survival data for monalizumab combination therapy in non-small cell lung cancer (NSCLC).

Why Innate Pharma Shares Are Rising On Friday?

AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial

Monalizumab and ANKET™ Data Will Be Presented at ESMO 2021 Virtual Congress

Innate Pharma SA (NASDAQ: IPHA) has announced its Phase 2 FORCE trial evaluating avdoralimab in COVID-19 patients with severe pneumonia did not meet its primary endpoints in all three cohorts trial. Based on these results, the Company will stop exploring avdoralimab in COVID-19.

Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints

Investigator-sponsored FORCE trial did not meet primary endpoints

Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

Innate Pharma SA (NASDAQ: IPHA) has announced preliminary data from the mycosis fungoides (MF) cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab. Data were shared at the International Conference on Malignant Lymphoma.

Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients

Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET™ Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET™

Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy

MARSEILLE, France, June 10, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced it will present the latest preclinical data from its next- generation, proprietary, multi-specific NK cell engager platform known as ANKET™ (Antibody-based NK cell Engager Therapeutics) at the Federation of Clinical Immunology Societies (FOCIS) meeting. The presentation will take place at 7 pm CEST today.

Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting

First clinical data of mycosis fungoides presented from the TELLOMAK trial First clinical data of mycosis fungoides presented from the TELLOMAK trial

New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma

MARSEILLE, France, May 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 28, 2021, in Marseille, France without the physical presence of its shareholders. All resolutions were voted on in accordance with the Executive Board's recommendations.

Outcome of Innate Pharma's Annual General Meeting

MARSEILLE, France, May 12, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) has published the convening notice to the Bulletin des Annonces Légales Obligatoires for its Annual General Meeting of Shareholders (“AGM”), which will take place virtually at 11:00 a.m. CEST on May 28, 2021.

Innate Pharma Virtual 2021 Annual General Meeting

Innate Pharma S.A. (IPHYF) CEO Mondher Mahjoubi on Q1 2021 Results - Earnings Call Transcript

News for Innate Pharma SA Stock (IPHA)